Kyverna Therapeutics (NASDAQ:KYTX) Now Covered by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX) in a research report sent to investors on Wednesday, Marketbeat reports. The brokerage issued a neutral rating and a $8.00 price objective on the stock.

Kyverna Therapeutics Price Performance

Shares of KYTX stock opened at $7.68 on Wednesday. The business’s 50-day moving average price is $12.32. Kyverna Therapeutics has a 12-month low of $6.75 and a 12-month high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Tuesday, May 14th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.28). During the same period in the prior year, the company posted ($12.10) earnings per share. Equities research analysts anticipate that Kyverna Therapeutics will post -3.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of large investors have recently added to or reduced their stakes in KYTX. DekaBank Deutsche Girozentrale bought a new position in shares of Kyverna Therapeutics during the first quarter valued at about $181,000. Teachers Retirement System of The State of Kentucky bought a new position in Kyverna Therapeutics during the 1st quarter worth approximately $313,000. StemPoint Capital LP bought a new position in Kyverna Therapeutics during the 1st quarter worth approximately $1,018,000. Blackstone Inc. purchased a new position in Kyverna Therapeutics in the 1st quarter worth approximately $2,484,000. Finally, Artal Group S.A. bought a new stake in Kyverna Therapeutics in the first quarter valued at approximately $4,968,000. Hedge funds and other institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.